Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Deep genomic characterisation of pediatric acute myeloid leukemia

ABSTRACT: Deep genomic characterisation of pediatric acute myeloid leukemia

PROVIDER: PRJNA923810 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23073300_1.fastq.gz	Fastqsanger.gz
	SRR23073300_2.fastq.gz	Fastqsanger.gz
	SRR23073301_1.fastq.gz	Fastqsanger.gz
	SRR23073301_2.fastq.gz	Fastqsanger.gz
	SRR23073302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 86

Similar Datasets

Deep genomic characterisation of pediatric acute myeloid leukemia

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-05-02 | GSE222903 | GEO

Transcriptome Analysis of Pediatric Acute Myeloid Leukemia

Project description:Transcriptome Analysis of Pediatric Acute Myeloid Leukemia

| PRJNA792548 | ENA

High-Resolution Genomic Profiling of Adult and Pediatric Core-Binding-Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Alterations

Project description:To identify cooperating lesions in core-binding-factor acute myeloid leukemia (CBF-AML), we performed single-nucleotide polymorphism (SNP)-array analysis on 300 diagnostic and 41 relapse adult and pediatric leukemia samples. We identified a mean of 1.28 copy number alterations (CNAs) per case at diagnosis in both patient populations. Recurrent minimally deleted regions (MDRs) were identified at 7q36.1 (7.7%), 9q21.13 (5%), 11p13 (2.3%), and 17q11.2 (2%). Recurrent focal gains were identified at 8q24.21 (4.7%) and 11q25 (1.7%), both containing a single non-coding RNA. Recurrent regions of copy-neutral loss-of-heterozygosity were identified at 1p (1%), 4q (0.7%), and 19p (0.7%), with known mutated cancer genes present in the minimally altered region. Analysis of relapse samples identified recurrent MDRs at 3q13 (12.2%), 5q (4.9%), and 17p (4.9%). SNP genotyping was performed on 300 adult and pediatric CBF-AMLs; t(8;21), n=157 (adult, n=114; pediatric, n=43); and inv(16), n=143 (adult, n=104; pediatric, n=39). Germline control DNA from remission bone marrow or peripheral blood was available for paired analysis in 175 patients. In addition, for 41 patients, matched relapse samples were analyzed. Data were processed using reference alignment, dChipSNP and circular binary segmentation.

2012-02-07 | E-GEOD-32462 | biostudies-arrayexpress

Global gene expression of pediatric acute myeloid leukemia

Project description:Global gene expression of pediatric acute myeloid leukemia

| PRJNA736703 | ENA

Genome wide DNA methylation of pediatric acute myeloid leukemia

Project description:Genome wide DNA methylation profiling of pediatric acute myeloid leukemia obtained from bone marrow. The Illumina EPIC methylation beadchip array was used to obtain DNA methylation profiles across approximately 850,000 CpG dinucleotide methylation loci in DNA isolated from leukemia. Samples include 64 patients.

2022-01-01 | GSE133986 | GEO

Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia

Project description:Genome wide DNA methylation profiling of pediatric acute myeloid leukemia (AML) from diagnostic and relapsed specimens.

2021-12-15 | GSE190931 | GEO

Transcriptome Analysis of Pediatric Acute Myeloid Leukemia

Project description:Purpose: This study aimed to generate a whole transcriptome dataset for children with acute myeloid leukemia Methods: RNA-seq data were generated by deep sequencing using Illumina. The sequence reads that passed quality filters were analyzed. Results: Using an optimized data analysis workflow, we mapped about 30 million sequence reads per sample to the human genome (buildhg38) and annotated with ensemble release 100.

2022-08-16 | GSE192638 | GEO

Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia.

Project description:Pediatric acute myeloid leukemia (AML) is an uncommon but aggressive hematological malignancy. The poor outcome is attributed to inadequate prognostic classification and limited treatment options. A thorough understanding on the genetic basis of pediatric AML is important for the development of effective approaches to improve outcomes. Here, by comprehensively profiling fusion genes as well as mutations and copy number changes of 141 myeloid-related genes in 147 pediatric AML patients with subsequent variant functional characterization, we unveil complex mutational patterns of biological relevance and disease mechanisms including MYC deregulation. Also, our findings highlight TP53 alterations as strong adverse prognostic markers in pediatric AML and suggest the core spindle checkpoint kinase BUB1B as a selective dependency in this aggressive subgroup. Collectively, our present study provides detailed genomic characterization revealing not only complexities and mechanistic insights into pediatric AML but also significant risk stratification and therapeutic strategies to tackle the disease.

| S-EPMC10066286 | biostudies-literature

Genome wide DNA methylation of pediatric acute myeloid leukemia

Project description:Genome wide DNA methylation of pediatric acute myeloid leukemia

| PRJNA553250 | ENA

Mnx1 Induces Leukemia Transformation Through Altering Histone Methylation in a Model of Pediatric t(7;12) Acute Myeloid Leukemia

Project description:Acute myeloid leukemia (AML) in children with cytogenetic aberrations like translocation t(7;12)(q36;p13) is associated with inferior outcome. The translocation can lead to a fusion transcript MNX1::ETV6 but also to activation of MNX1 transcription. We generated an AML mouse model by transplantation of fetal liver cells with ectopic expression of MNX1. AML was highly penetrant in immunocompromised and less penetrant in immunocompetent mice. Transforming capacity was restricted to fetal liver cells and could not achieved with adult bone marrow cells, in concordance with the clinical finding that t(7;12)(q36;p13) is mostly restricted to infants. Ectopic expression of MNX1 led to increased H3K4methylation and reduced H3K27me3, possibly through its interaction with methyl transferases. MNX1 expression was accompanied with changes in genome wide chromatin accessibility , increased DNA damage, depletion in the LSK population and skewing toward the myeloid lineage. These effects, together with leukemia development, could be prevented by the S-adenosylmethionine analogue Sinefungin that acts as a SAM competitor and a pan methyltranferases inhibitor. Expression profiles of a human iPSC AML model with t(7;12) and of TARGET pediatric AML and TCGA patients support the rationale for targeting MNX1 and downstream pathways.

2024-09-30 | PXD034416 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data